Posts Feed
Comments Feed

Synvista Therapeutics Announces Initiation Of Phase 2 Study With Alagebrium For Chronic Heart Failure

Synvista Therapeutics, Inc. (AMEX: SYI) announced , dosing of the first patient in BENEFICIAL, a 100-patient Phase 2 clinical trial of alagebrium (ALT-711), a novel compound designed to act as an Advanced Glycation End-product (AGE)-cross-link breaker, in patients with chronic heart failure (CHF). [click link for full article]

More: continued here

No Comments »

Trackback URI | Comments RSS

Leave a Reply

You must be logged in to post a comment.

1